COVID-19 vaccine effectiveness
(Randomized evidence)

If you want to see all comparisons, please click here

BioNTech/Fosun Pharma/Pfizer - BNT162b2 vs Placebo

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
(last update: 2021-06-18)

Trial subgroup analysis
(last update: 2021-01-18)

Evidence profile
2021-06-24

Summary of findings
2021-06-24

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04368728
Pfizer/BioNTech + Fosun Pharma
Frenck R, N Engl J Med, 2021

Full text
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 3
Adolescents aged 12 to 15 years with no previous Covid-19 diagnosis or SARS-CoV-2 infection in 29 centers in the USA N=2264
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech + Fosun Pharma
Polack F, N Engl J Med, 2020

Full text
Commentary
; Commentary
; Commentary
; Commentary
; Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2/3
Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA N=43448
Some concerns
Details

Full description

NCT04368728
BioNTech SE, Pfizer
Walsh E, N Engl J Med, 2020

Full text
Commentary
RNA based vaccine

BNT162b1 10 mcg D1/21

BNT162b1 20 mcg D1/21

BNT162b1 30 mcg D1/21

BNT162b1 100 mcg D1/21

BNT162b2 10 mcg D1/21

BNT162b2 20 mcg D1/21

BNT162b2 30 mcg D1/21

BNT162b1 30 mcg D1/21

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA N=195
Low
Details

Full description

NCT04523571 ; ChiCTR
BioNTech / Pfizer / Fosun Pharma
Zhu F, ResearchSquare, 2021

Full text
Commentary
; Commentary
RNA based vaccine

BNT126b1 10 mcg/0.5 ml 2-

BNT126b1 30 mcg/0.5 ml 2-

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 and 65-85 at a single center in China N=144
Some concerns
Details

Full description